MUMBAI (Reuters) – Mid-sized drugmaker Venus Remedies is in talks with various firms in the U.S. and Europe to out-license four patent drugs over the next 2-3 years, its top official said.
“We have short-listed a few companies in Europe, while talks are on with a few in the U.S. as we look to launch our four patented drugs by 2014,” Pawan Chaudhary, chairman and managing director, told Reuters late on Wednesday.
The Haryana-based drugmaker obtained a U.S. patent for ‘Vancoplus’, a drug to treat hospital acquired staph infections (MRSA), which has an estimated market size of $5 billion in the U.S., it said in a statement on Wednesday.
Methicillin-resistant Staphylococcus aureus or MRSA infection is caused by a strain of staph bacteria that become resistant to the antibiotics commonly used to treat staph infections.
“MRSA is a growing concern in the U.S. and the market for (MRSA) treatment is expect to reach $9 billion in another five years,” he said.
The company expects ‘Vancoplus’ to capture at least 5 percent market share in the U.S. in three years after its proposed launch in early 2014.
“The sales are growing fast in India and we expect 50 percent year-on-year growth from present sales of $4 million.”
Venus also wants to out-license its anti-infectant ‘Sulbactomax’, pneumonia drug ‘Potentox’ and one-a-day pain killer ‘Achnil’.
“We see substantial one-time licensing fees coming from all the four drugs by 2014, post which, our company will see a complete turn around.”
The drugs would also generate significant royalty from partners on large volumes, he added.
Last year, Venus had said, it expected Sulbactomax to capture 10 percent market share in Europe by 2015 with yearly sales reaching 25-30 million euros.